GHRS
GH Research Plc
NASDAQ · Healthcare · Biotechnology · IE
$18.28
+0.72%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -51.8%
- EBIT
- -34.8%
- EPS
- -35.1%
- Free cash flow
- -30.1%
- Operating cash flow
- -30.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -45.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- -23.0%
- EBIT
- -20.6%
- Net income
- -23.9%
- EPS
- -5.3%
- Free cash flow
- -3.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026